Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation

被引:10
|
作者
Yoshimura, Akihiro [1 ]
Yamada, Tadaaki [1 ]
Okura, Naoko [1 ]
Takeda, Takayuki [2 ]
Hirose, Kazuki [3 ]
Kubota, Yutaka [3 ]
Shiotsu, Shinsuke [4 ]
Hiranuma, Osamu [5 ]
Chihara, Yusuke [1 ]
Tamiya, Nobuyo [1 ]
Kaneko, Yoshiko [1 ]
Uchino, Junji [1 ]
Takayama, Koichi [1 ]
机构
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan
[2] Uji Tokushukai Med Ctr, Dept Resp Med, Kyoto 6110041, Japan
[3] Japanese Red Cross Kyoto Daini Hosp, Dept Resp Med, Kyoto 6028026, Japan
[4] Japanese Red Cross Kyoto Daiichi Hosp, Dept Resp Med, Kyoto 6050981, Japan
[5] Otsu City Hosp, Dept Resp Med, Otsu, Shiga 5200804, Japan
关键词
osimertinib; EGFR-T790M mutation; non-small cell lung cancer; biomarker; retrospective study; GROWTH-FACTOR; ACQUIRED-RESISTANCE; GEFITINIB; AZD9291; T790M;
D O I
10.3390/cancers11030365
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, the factors affecting response to osimertinib treatment are unknown. In this retrospective study, 27 NSCLC patients with the EGFR-T790M mutation were enrolled at five institutions in Japan. Among several parameters tested, the progression-free survival (PFS) associated with the initial EGFR-TKIs was positively correlated with the PFS after osimertinib treatment (p = 0.021). The median PFS following osimertinib treatment and the overall survival (OS) were longer in patients who responded to osimertinib than in those who did not (17.7 months versus 3.5 months, p = 0.009 and 24.2 months versus 13.5 months, p = 0.021, respectively). A multivariate analysis demonstrated that the PFS with initial EGFR-TKIs was significantly related to the PFS with osimertinib treatment (p = 0.035), whereas osimertinib response was significantly related to the PFS and OS with osimertinib treatment (p = 0.016 and p = 0.006, respectively). Our retrospective observations indicate that PFS following the initial EGFR-TKI treatment and the response rate to osimertinib might be promising predictors for effective osimertinib treatment in NSCLC patients with the EGFR-T790M mutation.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
    Yamada, T.
    Yoshimura, A.
    Takeda, T.
    Shiotsu, S.
    Hiranuma, O.
    Chihara, Y.
    Uchino, J.
    Takayama, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1033 - S1033
  • [2] Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer
    Bertranou, Evelina
    Bodnar, Carolyn
    Dansk, Viktor
    Greystoke, Alastair
    Large, Samuel
    Dyer, Matthew
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 113 - 121
  • [3] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [4] Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate)
    Mersiades, Antony
    Pavlakis, Nick
    Kao, Steven
    John, Tom
    Lee, Chee Khoon
    Dawson, Sarah-Jane
    Wong, Stephen
    Tan, Lavinia
    Yip, Sonia
    Brown, Chris
    Livingstone, Ann
    Cheung, Yvonne
    Jurkovic, Hannora
    Stockler, Martin
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 199 - 200
  • [5] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [6] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [7] A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study
    Tang, Xin
    Li, Yuan
    Qian, Wen-lei
    Yan, Wei-feng
    Pang, Tong
    Gong, You-ling
    Yang, Zhi-gang
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (09) : 2475 - 2486
  • [8] A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study
    Xin Tang
    Yuan Li
    Wen-lei Qian
    Wei-feng Yan
    Tong Pang
    You-ling Gong
    Zhi-gang Yang
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2475 - 2486
  • [9] Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells
    Wang, Rou-Hsin
    Chang, Chien-Jen
    Chen, Chien-Hung
    Liu, Kuang-Kai
    Chao, Jui-, I
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (11) : 1309 - 1319
  • [10] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622